Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sterility guidance

This article was originally published in The Gray Sheet

Executive Summary

1Draft guidance released Dec. 12 updates and clarifies FDA's review process for 510(k) devices labeled as sterile, particularly those utilizing novel sterilization methods. The draft also explains what information to include in the 510(k) submissions. An increasing number of such devices rely on non-traditional sterilization methods, such as chlorine dioxide, high-intensity light or microwave radiation, which may carry substantial risk to human health, FDA says. The agency plans to inspect the manufacturing facilities before clearing a 510(k) device sterilized in a non-traditional way. The guidance does not apply to sterilizers themselves, reusable medical devices that are reprocessed in clinical settings or reprocessed single-use devices. Comments are due March 12, 2009

You may also be interested in...



IGBA Urges WIPO To Revoke Patent Database Support

The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.

AAM Criticizes Lower Health Care Costs Act

Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.

USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.
UsernamePublicRestriction

Register

MT026906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel